论文部分内容阅读
目的 探讨在异基因造血干细胞移植中能否采用纯化 CD34 + 造血干细胞混合一定量纯化 CD3+ T细胞移植达到既控制移植物抗宿主病 (GVHD)又保留移植物的抗白血病效应 (GVL )。 方法 (C5 7BL /6× 6 15 ) F1代接种 L 6 15白血病细胞株建立小鼠白血病模型作为移植受鼠 ,利用免疫磁珠纯化骨髓 CD34 + 造血干细胞及脾脏CD3+细胞 ,流式细胞仪分析纯化前后 CD34 +、CD3+细胞百分比 ,观察单纯移植 CD34 +细胞及混合不同数量级 CD3+细胞后受鼠生存时间、GVHD、GVL效应 ,移植后骨髓造血重建细胞来源。 结果 纯化 CD34 + 细胞 1× 10 6 移植组10 0 %死于白血病复发 ;CD34 +细胞 +纯化 CD3+细胞 (1× 10 7)移植组生存期明显延长 ,5 0 %死于白血病复发 ,无GVHD表现 ;CD34 + 细胞 +CD3+ 细胞 (5× 10 7)移植组长期存活 ,无白血病复发 ,无 GVHD表现 ;CD34 + 细胞 +CD3+细胞 (1× 10 8)移植组 6 2 .5 %死于 GVHD,37.5 %长期存活 ;CD34 + 细胞 +CD3+ 细胞 (1.5× 10 8)移植组 10 0 %死于GVHD。移植后生存时间 >6 0 d的受鼠骨髓造血重建细胞 y染色体检出率为 10 0 %。 结论 移植物中 CD3+细胞数量与 GVHD和 GVL效应密切相关 ,通过限定移植物中的 CD3+ 淋巴细胞的含量能够保留 GVL作用而有效控制GVHD发生
Objective To investigate the anti-leukemia effect (GVL) of allogeneic hematopoietic stem cell transplantation (GVHD) and graft-versus-host disease (GVHD) in patients with allogeneic hematopoietic stem cell transplantation. Methods (C5 7BL / 6 × 6 15) F1 generation was inoculated with L 6 15 leukemia cell line to establish murine leukemia model as a transplanted recipient. Purified CD34 + hematopoietic stem cells and spleen CD3 + cells were purified by flow cytometry The percentage of CD34 + and CD3 + cells before and after transplantation was observed. The survival time, GVHD and GVL effect of purely transplanted CD34 + cells and mixed CD3 + cells of different orders were observed. Results 10% of the purified CD34 + cells in 1 × 10 6 transplanted group died of leukemia recurrence. The survival of CD34 + cells and purified CD3 + cells (1 × 10 7) was significantly prolonged, and 50% died of leukemia recurrence without GVHD ; CD34 + cells + CD3 + cells (5 × 10 7) long-term survival without leukemia recurrence, no GVHD; CD34 + cells + CD3 + cells (1 × 10 8) % Of long-term survival; 10% of CD34 + cells + CD3 + cells (1.5 × 10 8) transplantation group died of GVHD. The detection rate of y chromosome in the reconstituted cells of bone marrow after BMT> 60 days after transplantation was 100%. Conclusions The number of CD3 + cells in the grafts is closely related to the effects of GVHD and GVL. GVHD can be effectively controlled by limiting the amount of CD3 + lymphocytes in the graft